ReNeuron Group Plc engages in the development of novel cell-based therapies that target significant areas of unmet medical need. It develops its core stem cell assets such as CTX neural cell line and human retinal progenitor cells. The company was founded by John David Sinden in 1997 and is headquartered in Pencoed, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company